

Biotin for Hair Loss: Teasing Out the Evidence

Allyson Yelich, DO¹; Hannah Jenkins, BS²; Sara Holt, DO¹; and Richard Miller, DO¹

¹HCA Healthcare/USF Morsani College of Medicine GME; HCA Florida Largo Hospital, Department of Dermatology, Largo, FL; ²Lake Erie College of Osteopathic Medicine, Bradenton, FL




Figure 1. Summary of review conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.

| Results | | | | |
|--|---|------------------------|--|---|
| Table 1. Summary of the three studies that met our inclusion criteria. | | | | |
| Study | Population | Dose | Study Design | Results |
| ⁹ Pawlowski et al., 1966 | Females with diffuse pattern hair loss | 10 mg daily x 4 weeks | Double-blinded, placebo controlled; Group 1: 28 patients took biotin; Group 2: 18 patients took placebo | Both groups improved from baseline. No significant difference in hair growth or sebum production between groups. |
| ¹⁰ Aksac et al., 2021 | Patients taking isotretinoin | 10 mg daily x 4 months | Group 1: 30 patients took isotretinoin and biotin; Group 2: 30 patients took isotretinoin only | Using trichoscopy, both groups had a decrease in terminal hair density. Group 1 had a significant shift toward anagen hairs compared to baseline. |
| ¹¹ Sen et al., 2021 | Females with hair loss after sleeve gastrectomy | 1 mg daily | Group 1: 22 biotin-deficient patients took biotin x 3 months; Group 2: 29 biotin-sufficient patients took biotin x 2.5 months on average | 23% of Group 1 reported remarkable decline in hair loss. 38% of Group 2 reported remarkable decline in hair loss. There was no significant difference between groups. |

| Table 2. Laboratory tests susceptible to biotin interference. ^{12,13} | |
|--|--|
| Positive Interference (Falsely elevated) | Negative Interference (Falsely diminished) |
| Aldosterone Androstenedione Anti-HAV Total Anti-TSH receptor Anti-TPO Anti-Thyroglobulin (both) Cortisol Cyclosporine DHEAS Digoxin Estradiol Folate FT3, FT4, T3, T4 Progesterone Testosterone ¹⁴ Vitamin B12 Vitamin D Total 17-OH-progesterone 25-Hydroxyvitamin D | ACTH, FSH, GH, LH, PTH, SHBG, TSH AFP Anti-CCP Anti-HAV IgM Anti-HBc IgM & HBsAg Anti-HCV Calcitonin & Procalcitonin Cancer Ags (125, 15-3, 19-9, CEA, HE4, PSA) Cardiac biomarkers (Troponin, CK-MB, Myoglobin) EPO Ferritin Gastrin HIV 1/2 Ag/Ab ¹⁵ Insulin, IGF-1, C-peptide IgE NT-proBNP Prolactin Qualitative hCG ¹⁶ |

HAV, Hepatitis A virus; TSH, Thyroid stimulating hormone; TPO, Thyroid peroxidase; DHEAS, Dehydroepiandrosterone sulfate; FT3, Free triiodothyronine; FT4, Free thyroxine; ACTH, Adrenocorticotropic hormone; FSH, Follicle-stimulating hormone; GH, Human growth hormone; LH, Luteinizing hormone; PTH, Parathyroid hormone; SHBG, Sex hormone binding globulin; AFP, Alpha fetoprotein; CCP, Cyclic citrullinated peptide; Ig, Immunoglobulin; HBc, Hepatitis B core; HBsAg, Hepatitis B surface antigen; HCV, Hepatitis C virus; Ags, Antigens; CEA, Carcinoembryonic antigen; HE4, Human Epididymis Protein 4; PSA, Prostate-specific antigen; CK-MB, Creatine kinase-myocardial band; EPO, Erythropoietin; HIV 1/2 Ag/Ab, Human immunodeficiency virus 1/2 antigen/antibody test; IGF-1, Insulin-like growth factor 1; NT-proBNP, N-terminal pro-brain natriuretic peptide; hCG, Human chorionic gonadotropin.

Discussion

- Table 1 displays the three studies that met our inclusion criteria.
 - The study by Pawlowski et al. is almost 60 years old and did not support the use of biotin for diffuse female alopecia.⁹
 - The study on biotin's utility in isotretinoin-associated alopecia as well as the study on sleeve gastrectomy patients focused on niche patient populations and, therefore, are not generalizable.^{10,11} They also were not blinded, and therefore the results may have been affected by observer bias. Additionally, the results were not remarkably supportive of biotin.

Discussion Continued

- Despite minimal supporting evidence, biotin supplementation is pervasive in our society and recommended by many physicians for hair growth.^{17,18}
- Biotin supplementation does not come without risk. Elevated serum biotin levels can interact with various laboratory immunoassays that could lead to a missed diagnosis, needless workups, undue distress, or fatal consequences. Table 2 lists laboratory tests susceptible to biotin interference. The Food and Drug Administration (FDA) has released two safety communications to spread awareness about potentially serious interactions.
- Standard microgram doses (30-60 mcg daily) often found in multivitamins are believed not to interfere with streptavidin-biotin assays.¹⁹ Milligram doses (5-10 mg daily) can be found in over the counter supplements marketed for hair, skin, and nail growth, and can cause biotin interference, particularly in more sensitive assays like troponin.¹⁹
- Have patients stop biotin at least 2 days prior to laboratory testing (a week may be needed for high doses).^{19,20}

Conclusion

Our review displays that the widespread marketing of biotin for hair loss in healthy individuals is unsubstantiated. The current literature comprised of low-quality studies does not support superfluous biotin administration in individuals with sufficient levels. Additionally, the lack of awareness about biotin's potential laboratory interference poses a potential hazard. To appropriately justify or dispel biotin's popularity as a hair supplement, randomized-controlled studies on biotin monotherapy for improving hair growth or quality in the target population (i.e., healthy individuals with self-perceived hair loss) are especially needed.

References

- Patel DP, et al. A Review of the Use of Biotin for Hair Loss. *Skin Appendage Disord.* 2017 Aug;3(3):166-169.
- Zempleni J, et al. Biotin and biotinidase deficiency. *Expert Rev Endocrinol Metab.* 2008 Nov 13;6(7):715-724.
- Bistas KG, Tadi P. Biotin. [Updated 2023 May 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK554493/>
- National Institutes of Health Office of Dietary Supplements. Biotin – fact sheet for health professionals. (2022). Accessed: August 15, 2023; <https://ods.od.nih.gov/factsheets/Biotin-HealthProfessional/>
- Nosewicz J, et al. The epidemiology, impact, and diagnosis of micronutrient nutritional dermatoses. Part 2: B-complex vitamins. *J Am Acad Dermatol.* 2022 Feb;86(2):281-292.
- Almohanna HM, et al. The Role of Vitamins and Minerals in Hair Loss: A Review. *Dermatol Ther (Heidelberg).* 2019 Mar;9(1):51-70.
- Saleem F, Soos MP. Biotin Deficiency. 2023 Feb 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. PMID: 31615531.
- Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and Its Panel on Folate, Other B Vitamins, and Choline. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington (DC): National Academies Press (US); 1998. 11. Biotin. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK114297/>
- Pawlowski A, Kostanecki W. Effect of biotin on hair roots and sebum excretion in women with diffuse alopecia. *Pol Med J.* 1966;5(2):447-52.
- Aksac SE, et al. Evaluation of biophysical skin parameters and hair changes in patients with acne vulgaris treated with isotretinoin, and the effect of biotin use on these parameters. *Int J Dermatol.* 2021 Aug;60(8):980-985.
- Sen O, Turkkapar AG. Hair Loss After Sleeve Gastrectomy and Effect of Biotin Supplements. *J Laparoendosc Adv Surg Tech A.* 2021 Mar;31(3):296-300.
- Li D, et al. AACC Guidance Document on Biotin Interference in Laboratory Tests. *J Appl Lab Med.* 2020 May 1;5(3):575-587.
- Ostrowska M, et al. The effect of biotin interference on the results of blood hormone assays. *Endocrinol. Pol.* 2019;70(1):102-121.
- Stieglitz HM, et al. Suspected Testosterone-Producing Tumor in a Patient Taking Biotin Supplements. *J Endocr Soc.* 2018 May 10;2(6):563-569.
- Haleyur, Giti Setty MK, et al. Biotin Interference in Point of Care HIV Immunoassay. *Biores Open Access.* 2020 Nov 24;9(1):243-246.
- Williams GR, et al. Assessment of biotin interference with qualitative point-of-care hCG test devices. *Clin Biochem.* 2018 Mar;53:168-170.
- John JJ, et al. Assessment of biotin supplementation among patients in an outpatient dermatology clinic. *J Am Acad Dermatol.* 2019 Aug;81(2):620-621.
- Waags B, et al. A survey-based study of physician practices regarding biotin supplementation. *J Dermatolog Treat.* 2022 Feb;33(1):573-574.
- Trambas C, et al. Characterization of the scope and magnitude of biotin interference in susceptible Roche Elecsys competitive and sandwich immunoassays. *Ann Clin Biochem.* 2018 Mar;55(2):205-215.
- Gifford JL, et al. Strategies for mitigating risk posed by biotin interference on clinical immunoassays. *Clin Biochem.* 2019 Mar;65:61-63.

This research was supported (in whole or in part) by HCA Healthcare and/or an HCA Healthcare affiliated entity. The views expressed in this publication represent those of the author(s) and do not necessarily represent the official views of HCA Healthcare or any of its affiliated entities.